{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/atrial-fibrillation/background-information/complications-prognosis/","result":{"pageContext":{"chapter":{"id":"96a3b3f8-183a-52b6-9909-a81f0fd999dd","slug":"complications-prognosis","fullItemName":"Complications and prognosis","depth":2,"htmlHeader":"<!-- begin field 4b7c6d01-3737-4a3a-bf44-859876b22460 --><h2>What are the complications and prognosis?</h2><!-- end field 4b7c6d01-3737-4a3a-bf44-859876b22460 -->","summary":"","htmlStringContent":"<!-- begin item fbe8bd1f-33d2-4811-8a69-887d3a375db4 --><!-- begin field 0b6deb9f-b82a-46a5-80d3-5e6dd76e3837 --><ul><li><strong>Stroke and thromboembolism</strong> <strong>are the main complications of atrial fibrillation (AF).</strong><ul><li>People with AF have a greater risk of stroke and thromboembolism than people without AF. However, this risk is not homogeneous, and is dependent on the presence of various stroke <a class=\"topic-reference internal-reference\" href=\"/topics/atrial-fibrillation/management/management-of-af/#the-cha2ds2vasc-score-tool\">risk factors</a>.</li><li>Stroke severity is usually greater when stroke is associated with AF than with other causes.</li><li>Peripheral thromboembolism can also occur.</li></ul></li><li><strong>Heart failure </strong><strong>is commonly associated with AF.</strong><ul><li>Heart failure can occur because the disorganized electrical conduction in the atria results in ineffective ventricular filling.  The cardiac output can be reduced by as much as 10–20%, pushing an already compromised ventricle into failure.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li></ul></li><li><strong>Tachycardia-induced cardiomyopathy and critical cardiac ischaemia </strong><strong>may result from the persistently elevated ventricular rate seen in uncontrolled AF.</strong></li><li><strong>The mortality rate of people with AF appears to be correlated with the presence and severity of concomitant cardiovascular disease.</strong></li><li><strong>A large meta-analysis carried out in 2016 found that AF was associated with:</strong><ul><li>A 46% increase in all-cause mortality (data from 64 studies with 1,009,501 participants).</li><li>A 61% higher risk of ischaemic heart disease (data from 16 studies with 395,957 participants).</li><li>A 64% higher risk of chronic kidney disease (data from 3 studies with 467,000 participants).</li><li>An 88% higher risk of sudden cardiac death (data from 7 studies with 48,694 participants).</li><li>A 96% higher risk of a major cardiovascular event (data from 9 studies with 2,467,017 participants).</li><li>A two-fold increase in cardiovascular mortality (data from 14 studies with 342,453 participants).</li><li>A 2.3-fold increased risk of stroke (data from 38 studies with 6,143,925 participants).</li><li>A five-fold increased risk of congestive heart failure (data from 6 studies with 82,476 participants).</li></ul></li><li><strong>AF is also associated with reduced quality of life:</strong><ul><li>AF can result in reduced exercise tolerance and impaired cognitive function.</li><li>A systematic review of 49 studies found that people with AF have significantly poorer quality of life than healthy controls, the general population, and people with coronary heart disease.</li></ul></li><li><strong>The risks from <a class=\"topic-reference internal-reference\" href=\"/topics/atrial-fibrillation/background-information/definition/\">paroxysmal</a> AF are thought to be similar to those from <a class=\"topic-reference internal-reference\" href=\"/topics/atrial-fibrillation/background-information/definition/\">persistent</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/atrial-fibrillation/background-information/definition/\">permanent</a> AF.</strong></li><li><strong>Anticoagulation treatment reduces the risk of stroke by about two-thirds.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Thrall et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Fuster et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Camm et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">NICE, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">NICE, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Ruff et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Odutayo et al, 2016</a>]</p><!-- end field 0b6deb9f-b82a-46a5-80d3-5e6dd76e3837 --><!-- end item fbe8bd1f-33d2-4811-8a69-887d3a375db4 -->","topic":{"id":"c61747eb-a307-5da3-9878-9e952f2e1246","topicId":"e42fc175-7ae7-44c7-b7ef-b58a14733e7e","topicName":"Atrial fibrillation","slug":"atrial-fibrillation","lastRevised":"Last revised in October 2020","chapters":[{"id":"15747365-1cc2-550f-ad60-639db7df4ff0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ced6fef-0141-5375-b1c4-37d2756e7678","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75cb268e-28e7-51c1-87dd-0a86fbc0616b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1390db2e-6367-52cb-9af5-792d2e4d9310","slug":"changes","fullItemName":"Changes"},{"id":"f65a3e88-8f57-5c09-867a-ba88262e838c","slug":"update","fullItemName":"Update"}]},{"id":"16591b01-3ee5-5b14-a7e2-7a5226294933","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f3967a51-562c-5a5b-b55a-02dd39bfcbe9","slug":"goals","fullItemName":"Goals"},{"id":"5a66a5f8-9497-5664-abc1-d16cfe63bdd4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ca3b265-f279-56a1-94f0-c0e96dbeaaff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8bf96582-45d8-507c-9772-4c1092b4bd6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"992b55c8-2134-5283-b0f7-34608af53bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"677bafba-be09-57b3-a169-096ee3aa3fa1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6e491b1-6724-5c59-b127-fc29812ea52f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dab901c7-1cc0-5253-a4e0-e5b5bc04ba5e","slug":"definition","fullItemName":"Definition"},{"id":"39c5efdc-48cc-5b0a-85d7-f7da2de67a25","slug":"causes","fullItemName":"Causes"},{"id":"211e1811-bd20-5cfb-b7b9-c06c3fd223a3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"96a3b3f8-183a-52b6-9909-a81f0fd999dd","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"fc0c1acd-3cda-53a5-85ae-be117589c6bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a1e6d67-1c9c-5ea9-a30c-006e32e641c7","slug":"diagnosis-of-atrial-fibrillation","fullItemName":"Diagnosis of atrial fibrillation"}]},{"id":"42efe54e-8ff7-5283-ad5f-7dabdd2dcdff","fullItemName":"Management","slug":"management","subChapters":[{"id":"a955511a-8fbf-5bf9-aa82-b0e634a6325b","slug":"management-of-af","fullItemName":"Scenario: Management of AF"}]},{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2c20504-f7cb-54cc-adc0-c0cb70ec0ccb","slug":"beta-blockers-except-sotalol","fullItemName":"Beta-blockers (except sotalol)"},{"id":"d02a47f9-0498-503c-9cb1-0c3f89766d4f","slug":"diltiazem-verapamil","fullItemName":"Diltiazem and verapamil"},{"id":"037e75e8-454f-5dcd-a0b8-3e9ff5a5b309","slug":"digoxin","fullItemName":"Digoxin"},{"id":"c0c53c1d-4cd9-5e70-8a01-3d5f59d213cb","slug":"anticoagulants","fullItemName":"Anticoagulants"},{"id":"49e47ec1-0743-51db-a133-a2eed45d0eb0","slug":"aspirin-clopidogrel","fullItemName":"Aspirin and clopidogrel"},{"id":"5cb461d2-9502-5698-a467-30edd459c1b3","slug":"amiodarone-not-initiated-in-primary-care","fullItemName":"Amiodarone - not initiated in primary care"},{"id":"0fae1520-f160-57a2-af90-5b46bb20bdf5","slug":"sotalol-not-initiated-in-primary-care","fullItemName":"Sotalol - not initiated in primary care"}]},{"id":"1048ec97-41b1-5f93-a54d-1f58a8a56528","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5fff0dc2-1e01-590e-a159-76736c6a2ac0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b4497d2f-172b-54a5-99c6-5cd92c8469ba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d1d9c4e5-758a-5a99-93e3-4d2099a68d60","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0b86c2fd-54d8-569a-a8a8-ccadd53c17a0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e7ea1b2f-6198-53f7-b4f8-681296a03562","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3a114d83-bf8b-5507-b946-6af4f46c529e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5bbaf83e-cca2-55f4-a4c9-e6b808387a89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b6e491b1-6724-5c59-b127-fc29812ea52f","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}